NZ503073A - Inosine, guanosine and 6-thioguanine as stimulators or inhibitors of CNS axonal outgrowth - Google Patents

Inosine, guanosine and 6-thioguanine as stimulators or inhibitors of CNS axonal outgrowth

Info

Publication number
NZ503073A
NZ503073A NZ503073A NZ50307398A NZ503073A NZ 503073 A NZ503073 A NZ 503073A NZ 503073 A NZ503073 A NZ 503073A NZ 50307398 A NZ50307398 A NZ 50307398A NZ 503073 A NZ503073 A NZ 503073A
Authority
NZ
New Zealand
Prior art keywords
inosine
stimulators
thioguanine
guanosine
inhibitors
Prior art date
Application number
NZ503073A
Other languages
English (en)
Inventor
Larry I Benowitz
Original Assignee
Childrens Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens Medical Center filed Critical Childrens Medical Center
Publication of NZ503073A publication Critical patent/NZ503073A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
NZ503073A 1997-09-02 1998-02-20 Inosine, guanosine and 6-thioguanine as stimulators or inhibitors of CNS axonal outgrowth NZ503073A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/921,902 US6440455B1 (en) 1997-09-02 1997-09-02 Methods for modulating the axonal outgrowth of central nervous system neurons
PCT/US1998/003001 WO1999011274A1 (en) 1997-09-02 1998-02-20 Use of purine nucleosides for modulating the axonal outgrowth of central nervous system neurons

Publications (1)

Publication Number Publication Date
NZ503073A true NZ503073A (en) 2002-11-26

Family

ID=25446158

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ503073A NZ503073A (en) 1997-09-02 1998-02-20 Inosine, guanosine and 6-thioguanine as stimulators or inhibitors of CNS axonal outgrowth

Country Status (12)

Country Link
US (8) US6440455B1 (https=)
EP (2) EP1466606A3 (https=)
JP (1) JP4601816B2 (https=)
KR (1) KR100564789B1 (https=)
CN (1) CN1286632A (https=)
AT (1) ATE271874T1 (https=)
AU (1) AU748961B2 (https=)
CA (1) CA2302156C (https=)
DE (1) DE69825292T2 (https=)
NZ (1) NZ503073A (https=)
RU (1) RU2212241C2 (https=)
WO (1) WO1999011274A1 (https=)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6440455B1 (en) * 1997-09-02 2002-08-27 Children's Medical Center Corporation Methods for modulating the axonal outgrowth of central nervous system neurons
US20090297602A1 (en) * 1998-11-02 2009-12-03 Devane John G Modified Release Loxoprofen Compositions
MXPA01004381A (es) * 1998-11-02 2005-09-08 Elan Corp Plc Composicion de multiparticulado de liberacion modificada.
US7582680B1 (en) 1998-11-12 2009-09-01 Purdue Research Foundation Methods and compositions for treating mammalian spinal cord injuries
US7172871B1 (en) * 2000-09-07 2007-02-06 Children's Medical Center Corporation Methods and compositions for modulating axonal outgrowth of central nervous system neurons
FR2814077A1 (fr) * 2000-09-20 2002-03-22 Inst Nat Sante Rech Med Utilisation de modulateurs de recepteurs a l'adenosine pour reguler la fonction des netrines et/ou de leurs recepteurs
US7981420B2 (en) 2000-12-22 2011-07-19 Max-Planck-Gesellschaft Zur Foederung Der Wissenschaften E.V. Therapeutic use of antibodies directed against repulsive guidance molecule (RGM)
EP1389121B1 (en) 2001-04-24 2012-02-22 Purdue Research Foundation Method and compositions for treating mammalian nerve tissue injuries
US7147647B2 (en) * 2002-04-26 2006-12-12 Medtronic, Inc. Sintered titanium tube for the management of spinal cord injury
US20040106896A1 (en) * 2002-11-29 2004-06-03 The Regents Of The University Of California System and method for forming a non-ablative cardiac conduction block
US6904118B2 (en) * 2002-07-23 2005-06-07 General Electric Company Method and apparatus for generating a density map using dual-energy CT
US7813473B2 (en) * 2002-07-23 2010-10-12 General Electric Company Method and apparatus for generating temporally interpolated projections
AU2003264195A1 (en) * 2002-09-03 2004-03-29 Neurological Technologies Inc. Use of guanosine or inosine as anti-apoptotic agents in the treatment of i. a. neurodegenerative diseases or injuries at the nervous system
EP1556091A1 (en) * 2002-10-04 2005-07-27 Elan Pharma International Limited Gamma irradiation of solid nanoparticulate active agents
GB0228723D0 (en) 2002-12-09 2003-01-15 Cambridge Biotechnology Ltd Treatment of pain
AU2003300012A1 (en) * 2002-12-30 2004-07-29 Indiana University Research & Technology Corporation Method of treatment for central nervous system injury
EP1626742A1 (en) * 2003-05-22 2006-02-22 Elan Pharma International Limited Sterilization of dispersions of nanoparticulate active agents with gamma radiation
GB0312844D0 (en) * 2003-06-04 2003-07-09 Paradigm Therapeutics Ltd Use of compounds in medicine
WO2005016359A1 (en) * 2003-08-19 2005-02-24 Neurological Technologies Inc. Method of promoting remyelination
US8912144B2 (en) * 2003-12-16 2014-12-16 Children's Medical Center Corporation Method for treating stroke via administration of NEP1-40 and inosine
WO2006020365A2 (en) * 2004-07-26 2006-02-23 The Regents Of The University Of California Method for prevention or treatment of inflamatory disease
WO2006023530A2 (en) * 2004-08-16 2006-03-02 Massachusetts Institute Of Technology Compositions and methods for enhancing structural and functional nervous system reorganization and recovery
EP1855651A4 (en) * 2005-03-03 2011-06-15 Elan Pharma Int Ltd NANOPARTICLE COMPOSITIONS OF HETEROCYCLIC AMID DERIVATIVES
WO2006111348A1 (de) * 2005-04-18 2006-10-26 Abbott Gmbh & Co. Kg Verwendung von heparin und heparinderivaten zur modulation des neuritenwachstum-kontrollierenden nogo-rezeptors
EP1928905B1 (de) 2005-09-30 2015-04-15 AbbVie Deutschland GmbH & Co KG Bindungsdomänen von proteinen der repulsive guidance molecule (rgm) proteinfamilie und funktionale fragmente davon sowie deren verwendung
WO2007112986A1 (en) * 2006-03-31 2007-10-11 Adenobio N.V. Compositions, methods, and kits using adenosine and inosine in combination for diagnosis and treatment
AU2007272501A1 (en) * 2006-07-12 2008-01-17 Elan Pharma International Limited Nanoparticulate formulations of modafinil
WO2008070769A1 (en) * 2006-12-06 2008-06-12 Medtronic, Inc. Intrathecal catheter
US20080270686A1 (en) * 2007-04-26 2008-10-30 Grannan Michael F Methods and system to cache content on a vehicle
WO2009111264A2 (en) * 2008-02-29 2009-09-11 Alseres Pharmaceuticals, Inc. Systemic purine administration:modulating axonal outgrowth of central nervous system neurons
US8962803B2 (en) * 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
US8367352B2 (en) 2008-06-06 2013-02-05 Children's Medical Center Corporation Promoting axon regeneration in the adult CNS through control of protein translation
MX2012006560A (es) 2009-12-08 2012-10-05 Abbott Gmbh & Co Kg Anticuerpos monoclonales contra la proteina rgm a para utilizarse en el tratamiento de degeneracion de capa de fibra de nervio retinal.
EP3369746A1 (en) 2012-01-27 2018-09-05 AbbVie Deutschland GmbH & Co KG Composition and method for diagnosis and treatment of diseases associated with neurite degeneration
US20140179741A1 (en) * 2012-10-10 2014-06-26 Massachusetts Institute Of Technology Use of chelators of divalent cations to promote nerve regeneration
WO2014096958A1 (en) * 2012-11-02 2014-06-26 Academisch Medisch Centrum Inosine monophosphate and salts thereof for use in the treatment of complement-related disorders
RU2517117C2 (ru) * 2012-11-26 2014-05-27 Государственное бюджетное образовательное учреждение высшего профессионального образования "Казанский государственный медицинский университет" Министерства здравоохранения и социального развития Российской Федерации (ГБОУ ВПО Казанский ГМУ Минздравсоцразвития России) Способ стимулирования регенерации нерва с помощью наноструктурированного матрикса и генетических конструкций
KR102600879B1 (ko) * 2015-08-26 2023-11-09 가부시키가이샤 스타젠 세포 내 atp 증강제
WO2020140730A1 (zh) * 2018-12-30 2020-07-09 广州君赫生物科技有限公司 硫鸟嘌呤在制备治疗adsl缺陷症药物中应用
EP3797764A1 (en) 2019-09-27 2021-03-31 Janusz Chupty Contissi Pharmacological composition for treatment of nervous tissue dysfunction, in particular viral latency, and the use of j05 atc group substances in treatment of nervous tissue dysfunction, in particular viral latency
CA3183346C (en) * 2020-06-25 2024-01-02 Rajaram Samant Synergistic nutritional compositions for promoting axonal regeneration
WO2023055531A1 (en) * 2021-09-28 2023-04-06 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Methods for treating peripheral neuropathy

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3808027A (en) 1972-03-29 1974-04-30 Du Pont Silica surfaced films
US4341868A (en) * 1978-08-18 1982-07-27 Kyowa Hakko Kogyo Co., Ltd. Method and test composition for the determination of the substrate for xanthine oxidase
US4883666A (en) * 1987-04-29 1989-11-28 Massachusetts Institute Of Technology Controlled drug delivery system for treatment of neural disorders
WO1988009335A1 (en) 1987-05-26 1988-12-01 Paul Gordon Polymorphs of inosine and methods of making and using them
US5250414A (en) * 1988-11-04 1993-10-05 Erziehungsdirektion Of The Canton Zurich Diagnostic methods using neurite growth regulatory factors
US5187162A (en) 1989-09-15 1993-02-16 Gensia Pharmaceuticals Methods of treating neurodegenerative conditions
AU643235B2 (en) * 1989-09-15 1993-11-11 Gensia Pharmaceuticals, Inc. Methods of treating neurodegenerative conditions
RU1755583C (ru) * 1990-10-31 1994-08-30 ВНИИ генетики и селекции промышленных микроорганизмов Способ получения инозина
FR2692784B1 (fr) * 1992-06-24 1995-06-30 Pf Medicament Utilisation de la guanosine, de ses precurseurs et ses derives pour la fabrication de medicaments destines a traiter les deficits fonctionnels cerebraux.
US5483130A (en) * 1992-09-09 1996-01-09 Axelerator, Inc. Structure for accelerating heavy ions with uniformly spaced quadrupole focusing (USQF)
US5422343A (en) * 1992-12-21 1995-06-06 Otsuka Pharmaceutical Factory, Inc. Prophylactic and therapeutic composition for MRSA infection
US5438130A (en) * 1993-01-15 1995-08-01 Cambridge Neuroscience, Inc. Fucosylated guanosine disulfates as excitatory amino acid antagonists
RU2063753C1 (ru) 1993-04-22 1996-07-20 Василий Владимирович Афанасьев Способ лечения экстрапирамидного синдрома при остром отравлении галоперидолом
HUT73527A (en) * 1993-08-13 1996-08-28 Seikagaku Kogyo Co Ltd Remedy for nervous diseases
US5587384A (en) 1994-02-04 1996-12-24 The Johns Hopkins University Inhibitors of poly(ADP-ribose) synthetase and use thereof to treat NMDA neurotoxicity
RU2098085C1 (ru) * 1994-04-07 1997-12-10 Николай Васильевич Карсанов Антигипоксическое средство
US5447939A (en) * 1994-07-25 1995-09-05 Glasky; Alvin J. Carbon monoxide dependent guanylyl cyclase modifiers and methods of use
US5931809A (en) 1995-07-14 1999-08-03 Depotech Corporation Epidural administration of therapeutic compounds with sustained rate of release
US6440445B1 (en) * 1996-09-30 2002-08-27 Brigham & Women's Hospital Methods and compounds for treatment of abnormal uterine bleeding
US6440455B1 (en) * 1997-09-02 2002-08-27 Children's Medical Center Corporation Methods for modulating the axonal outgrowth of central nervous system neurons
US6855690B2 (en) * 2000-06-01 2005-02-15 Children's Medical Center Corporation Methods and compositions for treating ocular disorders
GB2379797A (en) * 2001-09-15 2003-03-19 Zarlink Semiconductor Ab Surface Emitting Laser

Also Published As

Publication number Publication date
US20020137721A1 (en) 2002-09-26
US7935680B2 (en) 2011-05-03
US20040014710A1 (en) 2004-01-22
DE69825292D1 (de) 2004-09-02
AU748961B2 (en) 2002-06-13
US6440455B1 (en) 2002-08-27
DE69825292T2 (de) 2005-05-25
CA2302156A1 (en) 1999-03-11
JP2001516695A (ja) 2001-10-02
RU2000108443A (ru) 2002-02-10
KR100564789B1 (ko) 2006-03-28
RU2212241C2 (ru) 2003-09-20
JP4601816B2 (ja) 2010-12-22
US6551612B2 (en) 2003-04-22
US20020042390A1 (en) 2002-04-11
ATE271874T1 (de) 2004-08-15
AU6656898A (en) 1999-03-22
CN1286632A (zh) 2001-03-07
US20020055484A1 (en) 2002-05-09
KR20010023578A (ko) 2001-03-26
US7338666B2 (en) 2008-03-04
WO1999011274A1 (en) 1999-03-11
HK1029916A1 (en) 2001-04-20
EP1466606A3 (en) 2004-11-24
EP1466606A2 (en) 2004-10-13
EP1009412B1 (en) 2004-07-28
US20070213294A1 (en) 2007-09-13
US20020128223A1 (en) 2002-09-12
CA2302156C (en) 2006-11-21
US20050277614A1 (en) 2005-12-15
EP1009412A1 (en) 2000-06-21

Similar Documents

Publication Publication Date Title
NZ503073A (en) Inosine, guanosine and 6-thioguanine as stimulators or inhibitors of CNS axonal outgrowth
EP0810863A4 (en) METHOD FOR TREATING ADENOSINE EXHAUST
ZA8953B (en) Phosphorus-containing squalene synthetase inhibitors,new intermediates and method
HUP9900006A3 (en) Cyclic gmp-specific phosphodiesterase inhibitors, their production and medicament containing them
PL323381A1 (en) Rotamase enzymatic activity inhibitors
NZ316361A (en) Rotamase enzyme activity inhibitors
DE69615165D1 (de) Verfahren zur regelung von enzymatischen reaktionen
PL313349A1 (en) Method of diagnoasing, progdnosticating and treating non-lymphatic tumours and their metastases
IL117845A0 (en) Compounds and methods for inhibiting hyper-proliferative cell growth
HUP0004826A3 (en) Method for treating and processing lupine seeds containing alkaloid, oil and protein
EP0670111A3 (de) Verfahren und Vorrichtung zur Bebrütung von Eiern.
ZA971566B (en) Method of treating leather with pmphoteric polymers.
AU1996599A (en) Long-term survival and regeneration of central nervous system neurons
FI962095A0 (fi) Menetelmä ja kantaja isomaltuloosin tuottamiseksi immobilisoiduilla mikro-organismeilla
ZA978129B (en) Method of treating leather with improved retanning agents.
IL125031A0 (en) Method for treating depression
IL149183A0 (en) System and method for adaptive trade specification and match-making optimization
EP0638586A3 (en) Nucleoside derivatives and process for their preparation.
EP0994186A4 (en) RAFFINOSE SYNTHETASE GENE, METHOD FOR PRODUCING RAFFINOSE, AND TRANSFORMED PLANT
EP0673236A4 (en) METHOD FOR STIMULATING THE PRODUCTION OF HEM OXYGENASE USING VITAMIN B12.
DE3567479D1 (en) Method and installation for heat treatment, especially case-hardening
GB8916425D0 (en) Method of chemical-thermal treatment of parts,diffusion coatings obtained by the proposed methods,and installation for realizing thereof
HUP0002318A3 (en) Process for stimulating neural regeneration
WO1999002659A3 (en) Method of altering the domains of cyclosporin synthetase to give a modified cyclosporin synthetase
AU4857796A (en) Sex-specific dna probe for parrots, methods and kits

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)